This category covers biotechnology and pharmaceutical companies developing therapies targeting ferroptosis — an iron-dependent form of regulated cell death characterized by lipid peroxidation accumulation — for the treatment of Parkinson's disease (PD). Ferroptosis is increasingly recognized as a key mechanism contributing to dopaminergic neuron loss in PD, with evidence pointing to impaired glutathione peroxidase 4 (GPX4) function, iron dyshomeostasis in the substantia nigra, and lipid peroxidation accumulation["@li2024"].
...
Overview
Mermaid diagram (expand to render)
This category covers biotechnology and pharmaceutical companies developing therapies targeting ferroptosis — an iron-dependent form of regulated cell death characterized by lipid peroxidation accumulation — for the treatment of Parkinson's disease (PD). Ferroptosis is increasingly recognized as a key mechanism contributing to dopaminergic neuron loss in PD, with evidence pointing to impaired glutathione peroxidase 4 (GPX4) function, iron dyshomeostasis in the substantia nigra, and lipid peroxidation accumulation["@li2024"].
Unlike apoptosis or necrosis, ferroptosis is distinctively characterized by:
Iron-dependent accumulation of lipid peroxides
Loss of GPX4 activity leading to membrane lipid damage
Sensitivity to iron chelation and lipid antioxidant treatment
Distinct morphological features (smaller mitochondria, dense membrane)
The substantia nigra pars compacta is particularly vulnerable to ferroptosis due to:
High iron accumulation in PD brains
Elevated ACSL4 expression making dopaminergic neurons highly sensitive
Dopamine oxidation generating reactive oxygen species
Limited antioxidant capacity compared to other neuronal populations
Companies in this space pursue several mechanisms targeting different nodes of the ferroptosis pathway, including iron chelation, GPX4 activation, lipid peroxidation scavenging, System Xc- modulation, and FSP1/CoQ10 augmentation.
Key Mechanisms
Iron Chelation
Reducing labile iron availability that drives Fenton reactions and lipid peroxide formation. Deferiprone and similar BBB-penetrant chelators have shown clinical data in PD.
GPX4 Activation
Restoring or enhancing GPX4 function to reduce lipid peroxides. Includes direct GPX4 modulators, selenium supplementation, and upregulation strategies.
Lipid Peroxidation Inhibition
Scavenging lipid peroxyl radicals before they damage membranes. Ferrostatin-1 analogs and lipophilic antioxidants.
System Xc- Modulation
The cystine/glutamate antiporter (SLC7A11/SLC3A2) imports cystine for GSH synthesis. Modulators can enhance this pathway to restore cellular antioxidant capacity.
FSP1/CoQ10 Augmentation
FSP1-mediated CoQ10 reduction provides alternative lipid peroxidation defense independent of GPX4.
Key Companies
Clinical-Stage Companies
Apopharma Inc. (Subsidiary of Chiesi Farmaceutici)
Focus: Iron chelation therapy
Lead Candidate: Deferiprone (Ferriprox/Kelfer)
Indication: Parkinson's disease
Stage: Phase II completed, Phase III planning
Mechanism: Oral iron chelator that crosses the blood-brain barrier and reduces brain iron stores implicated in ferroptosis
Clinical Data: FAIRPARK-II trial demonstrated significant brain iron reduction in substantia nigra and putamen, with signal of reduced disease progression on MDS-UPDRS[@devos2018][moreau2022]
Related Page: [Apopharma Inc.](/companies/apopharma)
Pharmaceutical companies with CoQ10 programs
Focus: CoQ10 supplementation for mitochondrial/ferroptosis protection
Lead Candidates: Ubiquinol, mitochondrial-targeted CoQ10
Indication: Parkinson's disease
Stage: Phase II/III
Mechanism: Supports FSP1-mediated ferroptosis defense through CoQ10 redox cycling
Notes: CoQ10 provides GPX4-independent lipid peroxidation protection via the FSP1 pathway
Preclinical/Research Stage Companies
Ferro Rx (Research Consortium)
Focus: GPX4-targeted small molecules
Lead Candidates: FRX-101, FRX-201 (research compounds)
Indication: Parkinson's disease / ALS
Stage: Discovery/Preclinical
Mechanism: Direct GPX4 activity modulators designed to prevent ferroptotic cell death in dopaminergic neurons
Notes: Academic-industry collaboration focused on ferroptosis modulation; working on BBB-penetrant analogs of known GPX4 modulators